Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 333

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

Targeting the PI3-kinase pathway in triple-negative breast cancer

Open access
Pascual, J., Turner, N.C. · 2019 · Annals of Oncology

Abstract

Triple negative breast cancer (TNBC) is characterised by poor outcomes and a historical lack of targeted therapies. Dysregulation of signalling through the PI3 kinase and AKT signalling pathway is one of the most frequent oncogenic aberrations of triple negative breast cancer. Although mutations in individual genes occur relatively rarely, combined activating mutations in PIK3CA and AKT1, with inactivating mutations in PTEN, occur in approximately 25-30% of advanced TNBC. Recent randomised trials suggest improved progression-free survival (PFS) with AKT-inhibitors in combination with first-line chemotherapy for patients with TNBC and pathway genetic aberrations. We review the evidence for PI3 kinase pathway activation in TNBC, and clinical trial data for PI3 kinase, AKT and mTOR inhibitors in TNBC. We discuss uncertainty over defining which cancers have pathway activation and the future overlap between immunotherapy and pathway targeting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdz133

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 88 references

Cited by

See all 333

Metadata

Authors
Pascual, J., & Turner, N. C.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-07
Volume
30
Issue
7
Pages
1051-1060
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2943363006
Cited by
333
References
88
FWCI
9.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the PI3-kinase pathway in triple-negative breast cancer. https://app.cochat.ai/papers/10.1093/annonc/mdz133
The paper
Pascual, J., & Turner, N. C. (2019). Targeting the PI3-kinase pathway in triple-negative breast cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mdz133

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.